BRAF and melanoma: To accomplish this, we screened a panel of 12 BRAF mutant melanoma cell lines for drugs or small molecule inhibitors that were synergistically cytotoxic with one of three MAP Kinase pathway inhibitors (PLX4720, RAF265 or PD325901).